Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05530187
Other study ID # IePRO
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date November 2, 2021
Est. completion date November 2, 2023

Study information

Verified date September 2022
Source University of Lausanne
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Immune checkpoint inhibitors (ICIs) can cause immune-related adverse events (IrAEs) throughout and beyond treatment duration. These IrAEs can be varied and difficult to predict, as they can involve almost any organ, regardless of where the primary tumor is located. Treatment modality and individual characteristics appear to influence the frequency and severity of these events, which can become serious without proper monitoring and timely intervention. Generally, patient visits are scheduled at the same intervals in which patients receive treatment, once every two to four weeks. In these large intervals, patients can be surprised by IrAEs without a close schedule visit to their oncology physician. Not only this may negatively influence their overall well-being, their perceived self-efficacy to manage their own condition and their health-related quality of life may be affected as well. Using patient-reported outcomes (PROs) to monitor patient symptoms has become incredibly valuable in describing treatment toxicity, including that of ICIs. PROs are a self-report of the patient's own perceptions of their health status. Using their own words, or by replying to questionnaires, patients can convey symptoms and how these affect their daily life and quality of life. Questionnaires are an example of a PRO measure (PROM), which have increasingly been provided electronically (resulting in electronic PROs or ePROs). The ubiquity of connected electronic devices has enabled long-distance monitoring of symptoms through electronic questionnaires. In patients treated with chemotherapy, studies have shown that using this method to collect symptom data can enable healthcare providers to help patients manage their symptoms remotely. This allows patients to receive timely support from home, that could help prevent serious complications that could entail visits to the emergency department, unscheduled hospitalizations and treatment interruptions. The IePRO study's aim is to test a model of care that uses electronic questionnaires to monitor symptoms that could be related to the use of ICIs. Patients would reply to these questionnaires at least once a week using an electronic web application (on their phone or computer). A team of oncology nurses reviews their replies and calls patients when new symptoms appear or when they worsen. Using a standard triage algorithm, the nurses guide patients on how to proceed: if they should stay home and follow self-care advice, if they should have a second call within the next 24 hours to follow-up on their symptoms, or if they should come to the hospital for an in-person assessment as soon as possible. In this study, it is hypothesized that this model of care could lead to an earlier detection of IrAEs, as well as their improved management by reducing the number of high-severity IrAEs, the number of unscheduled emergency admissions and hospitalizations, as well as decreasing the number of treatment interruptions and of immunosuppressive treatments used to treat IrAEs.


Recruitment information / eligibility

Status Recruiting
Enrollment 198
Est. completion date November 2, 2023
Est. primary completion date November 2, 2023
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Patients 18 years old or older - Patients diagnosed with cancer - Patients starting or re-starting systemic ICI therapy treatments (adjuvant, neo-adjuvant, metastatic) - Informed Consent as documented by signature Exclusion Criteria: - Patients that self-declare not being able to use an ePRO application and complete a questionnaire in French. - Patients with any psychological, familial or sociological condition and linguistic limitation potentially hampering compliance with the study protocol requirements and/or follow-up procedures. These conditions will be discussed between the recruiting oncologist and the patient before trial entry. - Patients that are re-starting ICI therapy, but that have previously participated in this intervention. - Patients with a cognitive impairment, as declared in the patient record - Patients participating in other interventional clinical studies.

Study Design


Related Conditions & MeSH terms


Intervention

Device:
Electronic Patient-reported Outcomes-based Model of Care
Patients in the intervention arm of this study will report symptoms weekly through an electronic symptom questionnaire. For the first 3 months of the 6 month intervention, they will reassess the reported symptoms daily. A team of oncology nurses will contact patients by telephone if they declare a new or worsening symptom. The nurses will use a triage algorithm to identify patient needs (self-care, remote follow-up or in-person assessment).

Locations

Country Name City State
Switzerland Hôpitaux Universitaires de Genève Geneva
Switzerland Centre Hospitalier Universitaire Vaudois Lausanne Vaud

Sponsors (1)

Lead Sponsor Collaborator
Manuela Eicher

Country where clinical trial is conducted

Switzerland, 

Outcome

Type Measure Description Time frame Safety issue
Primary IrAE time-to-detection The primary outcome is the difference (in days) between the symptom onset date and the date when it was detected by the oncology team. Through study completion, an average of 6 months
Secondary Number of symptomatic IrAEs experienced by patients Number, type and grade of diagnosed Symptomatic IrAEs. Up to 6 months
Secondary Number of self-reported symptoms Type and number of self-reported PRO-CTCAE items. Up to 6 months
Secondary Symptom-to-treatment interval Time (in days) between symptom onset and the first pharmacological intervention for the symptomatic IrAE. Up to 6 months
Secondary IrAE treatments Number and type of documented pharmacological interventions to manage IrAEs. Up to 6 months
Secondary Maximum IrAE grade Highest recorded IrAE grade according to the CTCAE version 5.0 Up to 6 months
Secondary Health-related Quality of Life score measured with the FACT-G questionnaire Change from baseline in health-related quality of life (weekly and at 6 months) Up to 6 months
Secondary Self-efficacy score as measured with the PROMIS Self-Efficacy for Managing Symptoms short form 8a questionnaire Change from baseline in perceived self-efficacy to manage symptoms (weekly and at 6 months) Up to 6 months
Secondary Overall survival Overall survival at 6 months. Up to 6 months
Secondary Triage process Type and amount of IrAE management actions/instructions issued by triage nurses, per resulting alerts (green, amber and red alerts). Up to 6 months
See also
  Status Clinical Trial Phase
Not yet recruiting NCT05958108 - Effectivenness and Implementation of an Intervention to Improve Primary Care Patient Safety Phase 3
Not yet recruiting NCT06043895 - EpiFaith CV for Central Venous Catheterization N/A
Recruiting NCT02574104 - Generalizing TESTPILOT to New Single Family Room NICUs N/A
Completed NCT00599209 - Health Information Technology in the Nursing Home N/A
Completed NCT04576299 - Health Care Workers' Perception of Patient Safety During COVID-19 Pandemic
Completed NCT03663491 - Necessity of Transnasal Gastroscopy in Routine Diagnostics - a Patient Centered Requirement Analysis N/A
Completed NCT00212927 - Continuity of Care and Outcomes After Discharge From Hospital N/A
Not yet recruiting NCT05062434 - An Intervention to Impact Cardiovascular Implantable Electronic Device Lead Models Implanted in Veterans N/A
Recruiting NCT06089239 - De-Implementing Fall Prevention Alarms in Hospitals N/A
Recruiting NCT04861025 - Siderails as a Measure of Physical Restraint. GERBAR Trial
Completed NCT04990986 - Co-Development and Evaluation of a Complex Intervention to Increase Medication Safety in Nursing Homes N/A
Recruiting NCT02955836 - Effectiveness of Monitoring Information System of Nursing Related Patient Safety and Quality Indicators N/A
Completed NCT01246544 - Helsinki Declaration on Patient Safety N/A
Recruiting NCT04176094 - Intensive Care Unit Resident Scheduling Trial N/A
Completed NCT05794490 - Learning From Excellence in a Hospital Unit
Recruiting NCT06269250 - Acceptance and Perceived Benefits of Digitalization by Medical Assistants
Recruiting NCT03105713 - Development and Implementation of Patient Safety Checklists Before, During and After In-hospital Surgery N/A
Completed NCT04184570 - Audit of International Intraoperative Hemotherapy and Blood Loss Documentation
Recruiting NCT04897087 - Openness and Learning Joint Commission: Using Patient Experience for Improvement Following a Patient Safety Event
Active, not recruiting NCT06259812 - Machine Learning Prediction of Parameters of Early Warning Scores in Intensive Care Units